[1] Chen XS, Li WZ, Jiang C, Ye GY. Leprosy in China: epidemiological trends between 1949 and 1998. Bull World Health Organ 2001;79(4):306 − 12. https://www.ncbi.nlm.nih.gov/pubmed/11357209.https://www.ncbi.nlm.nih.gov/pubmed/11357209
[2] Yu MW, Zhang GC, Yan LW, Shen JP, Sun PW. Epidemiological analysis on leprosy in China, 2001-2010. Chin J Dermatol 2012;45(6):381 − 3. http://dx.doi.org/10.3760/cma.j.issn.0412-4030.2012.06.001 (In Chinese). CrossRef
[3] Tian WW, Shen JP, Zhou M, Yan LB, Zhang GC. Dapsone hypersensitivity syndrome among leprosy patients in China. Lepr Rev 2012;83(4):370 − 7. https://www.ncbi.nlm.nih.gov/pubmed/23614255.https://www.ncbi.nlm.nih.gov/pubmed/23614255
[4] WHO. Global leprosy update, 2018: moving towards a leprosy-free world. Wkly Epidemiol Rec 2019;94:389 − 412.
[5] Chen XS, Li WZ, Jiang C, Zhu ZL, Ye G. Computerization of leprosy records: national leprosy recording and reporting system in China. Lepr Rev 2000;71(1):47 − 56. https://www.ncbi.nlm.nih.gov/pubmed/10820987.https://www.ncbi.nlm.nih.gov/pubmed/10820987
[6] Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, et al. Genomewide association study of leprosy. N Engl J Med 2009;361:2609 − 18. http://dx.doi.org/10.1056/NEJMoa0903753CrossRef
[7] Zhang FR, Liu H, Chen SM, Low H, Sun LD, Cui Y, et al. Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet 2011;43(12):1247 − 51. http://dx.doi.org/10.1038/ng.973CrossRef
[8] Liu H, Irwanto A, Tian HQ, Fu XA, Yu YX, Yu GQ, et al. Identification of IL18RAP/IL18R1 and IL12B as leprosy risk genes demonstrates shared pathogenesis between inflammation and infectious diseases. Am J Hum Genet 2012;91(5):935 − 41. http://dx.doi.org/10.1016/j.ajhg.2012.09.010CrossRef
[9] Liu H, Bao FF, Irwanto A, Fu XA, Lu N, Yu GQ, et al. An association study of TOLL and CARD with leprosy susceptibility in Chinese population. Hum Mol Genet 2013;22(21):4430 − 7. http://dx.doi.org/10.1093/hmg/ddt286CrossRef
[10] Liu H, Irwanto A, Fu XA, Yu GQ, Yu YX, Sun YH, et al. Discovery of six new susceptibility loci and analysis of pleiotropic effects in leprosy. Nat Genet 2015;47(3):267 − 71. http://dx.doi.org/10.1038/ng.3212CrossRef
[11] Wang ZZ, Sun YH, Fu XA, Yu GQ, Wang C, Bao FF, et al. A large-scale genome-wide association and meta-analysis identified four novel susceptibility loci for leprosy. Nat Commun 2016;7(1):13760. http://dx.doi.org/10.1038/ncomms13760CrossRef
[12] Liu H, Wang ZZ, Li Y, Yu GQ, Fu XA, Wang C, et al. Genome-wide analysis of protein-coding variants in leprosy. J Invest Dermatol 2017;137(12):2544 − 51. http://dx.doi.org/10.1016/j.jid.2017.08.004CrossRef
[13] Wang N, Wang ZZ, Wang C, Fu XA, Yu GQ, Yue ZH, et al. Prediction of leprosy in the Chinese population based on a weighted genetic risk score. PLoS Negl Trop Dis 2018;12(9):e0006789. http://dx.doi.org/10.1371/journal.pntd.0006789CrossRef
[14] Liu J, Shang XJ, You YG, Xing Y, Yuan LC, Duthie MS, et al. Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, Southwest China. Trans Roy Soc Trop Med Hyg 2019. http://dx.doi.org/10.1093/trstmh/trz089CrossRef
[15] Chen XH, You YG, Yuan YH, Yuan LC, Zhang Y, Yan W. Evaluation of antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China. PLoS Negl Trop Dis 2018;12(9):e0006777. http://dx.doi.org/10.1371/journal.pntd.0006777CrossRef
[16] Wen Y, You YG, Yuan LC, Yuan YH, Zhang Y, Duthie MS, et al. Evaluation of novel tools to facilitate the detection and characterization of leprosy patients in China. Biomed Res Int 2014;2014:371828. http://dx.doi.org/10.1155/2014/371828CrossRef
[17] Pan QH, Zheng ZY, Yang J, Wen Y, Yuan LC, Li HY, et al. Early revelation of leprosy in China by sequential antibody analyses with LID-1 and PGL-I. J Trop Med 2013;2013:352689. http://dx.doi.org/10.1155/2013/352689CrossRef
[18] Chen XH, You YG, Yuan YH, Yuan LC, Wen Y. Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole-blood assay correlate with the diagnosis of paucibacillary leprosy patients in China. PLoS Negl Trop Dis 2019;13(4):e0007318. http://dx.doi.org/10.1371/journal.pntd.0007318CrossRef
[19] Chen XH, Xing Y, He J, Tan FY, You YG, Wen Y. Develop and field evolution of single tube nested PCR, SYBRGreen PCR methods, for the diagnosis of leprosy in paraffin-embedded formalin fixed tissues in Yunnan Province, a hyper endemic area of leprosy in China. PLoS Negl Trop Dis 2019;13(10):e0007731. http://dx.doi.org/10.1371/journal.pntd.0007731CrossRef
[20] Cheng XJ, Sun LL, Zhao Q, Mi ZH, Yu GQ, Wang ZZ, et al. Development and evaluation of a droplet digital PCR assay for the diagnosis of paucibacillary leprosy in skin biopsy specimens. PLoS Negl Trop Dis 2019;13(3):e0007284. http://dx.doi.org/10.1371/journal.pntd.0007284CrossRef
[21] Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013;369(17):1620 − 8. http://dx.doi.org/10.1056/NEJMoa1213096CrossRef
[22] Wang HS, Yan LB, Zhang GC, Chen XS, Yang J, Li M, et al. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. J Invest Dermatol 2013;133(11):2642 − 4. http://dx.doi.org/10.1038/jid.2013.192CrossRef
[23] Chiramel M, George R, Daniel D, Sam Arul Das R, Mani V, Antonisamy B, et al. Case-control study measuring the association between HLA-B*13: 01 and dapsone hypersensitivity syndrome in Indian patients. Lepr Rev 2019; 90(4):371-7. https://www.leprosy-information.org/resource/case-control-study-measuring-association-between-hla-b1301-and-dapsone-hypersensitivity.https://www.leprosy-information.org/resource/case-control-study-measuring-association-between-hla-b1301-and-dapsone-hypersensitivity
[24] Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13:01 allele in the Thai population. Pharmacogenet Genomics 2017;27(12):429 − 37. http://dx.doi.org/10.1097/FPC.0000000000000306CrossRef
[25] Liu H, Wang ZZ, Bao FF, Wang C, Sun LL, Zhang HM, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol 2019;155(6):666 − 72. http://dx.doi.org/10.1001/jamadermatol.2018.5360CrossRef